BioCina expands partnership with GPN Vaccines

BioCina Pty Ltd., a global end-to-end biologics CDMO, announced the expansion of their partnership with GPN Vaccines Ltd.

GPN Vaccines is a biotechnology company developing a proprietary engineered whole-cell vaccine called Gamma-PNTM against Streptococcus pneumoniae. This bacterium is responsible for causing life-threatening infections such as pneumonia, bacteraemia and meningitis, each year causing up to 2 million deaths worldwide. GPN’s vaccine technology is a proprietary engineered strain of Streptococcus pneumoniae that lacks capsular polysaccharide and expresses surface proteins common to all serotypes, inducing broad-spectrum T- and B-cell immunity to cross-reactive protein antigens of the bacteria, making this vaccine outperform against currently approved vaccines.

BioCina will manufacture large-scale cGMP batches for this programme. The BioCina facility in Adelaide, Australia has a rich history of developing and manufacturing recombinant proteins in microbial systems such as E. coli.

BioCina’s chief executive officer, Mark W. Womack stated, “We are extremely proud that GPN Vaccines has asked us to further scale-up the production of Gamma-PNTM, which has the potential to protect so many lives against a broad range of serotypes not covered by any current vaccines.”

GPN Vaccines’ chairman & chief executive officer, Professor Tim Hirst said, “We are delighted to be progressing with the next stage of cGMP manufacture of our innovative whole cell pneumococcal vaccine, Gamma-PNTM, with BioCina as the CDMO of choice. They successfully optimised the manufacture of phase 1 material, and we now look forward to working with them to deliver a scaled-up process for the manufacture of phase 2 material suitable for clinical evaluation worldwide.”

BioCina is a global end-to-end biologics contract development and manufacturing organization (CDMO) of choice, offering process development and cGMP clinical & commercial manufacturing of the microbial, plasmid DNA and mRNA modalities.

GPN Vaccines is a public (unlisted) biotechnology company developing a vaccine against Streptococcus pneumoniae, which is responsible for causing life-threatening pneumonia, bacteremia, and meningitis, as well as otitis media (middle ear infections).

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!